23andMe Investor Day Presentation Deck

23ME '610 Targeting CD200R1: A Genetically- Validated Approach to Anti-Cancer Therapy 23andMe's I/O signature highlights potential targets with genetic evidence of importance • CD200R1 is an immune checkpoint with a clearly defined I/O signature in three components of the pathway • CD200R1 ligand is highly expressed in a subset of human cancers • 23ME '610 is a potent monoclonal antibody against CD200R1 that has the potential to restore T-cell killing of cancer cells • The Phase 1 study of 23ME '610 in patients with advanced solid malignancies has been initiated and the first patient was dosed in January 2022 Copyright © 2022 23andMe, Inc. 23andMe® 42

View entire presentation